There is no doubt that the interest and hype around blockchain, or distributed ledger technology (DLT), builds daily. The explosion of articles and books recently is testament to this. But what is a blockchain and how might distributed ledger technology impact healthcare, Pharma and R&D?
In a new article on pages 52-57 of the Fall edition of Drug Discovery World Curlew Research Consultant Richard Shute shines a light on some of the blockchain use-cases that might be more beneficial and compelling within the healthcare industry, and more specifically in drug discovery R&D. The article builds on four of the fundamental aspects of blockchain technology: Identity, Timestamping, Content and Immutability (ITCI) and describes use-cases around IP, genomic and other research data management, and digital identity – to name but four.
Many thought-leaders have written on blockchain use-cases post-R&D, for example in the medicines’ supply chain; Curlew Research maintains that DLT will also disrupt the pre-submission, R&D space. To find out more about blockchain in R&D, go to the article or contact Curlew Research via https://curlewresearch.com/contact/.